The use of COX-2 inhibitors for acute dental pain: A second look

Journal of the American Dental Association

Volumn 137, Issue 4, 2006, Pages 480-487

  Huber, Michaell A ^a   Terezhalmy, Geza T ^a  

^a UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

Author keywords

Acute dental pain; Adverse drug events; Cyclo oxygenase 2 inhibitor; Ibuprofen

Indexed keywords

EID: 33646349493     PISSN: 00028177     EISSN: None     Source Type: Journal    
DOI: 10.14219/jada.archive.2006.0220     Document Type: Article

References (49)

1. Daniels SE, Desjardins PJ, Talwalker S, Recker DP, Verburg KM. The analgesic efficacy of valdecoxib vs. oxycodone/acetaminophen after oral surgery. JADA 2002;133:611-21.
2. Fricke J, Varkalis J, Zwillich S, et al. Valdecoxob is more efficacious than rofecoxib in relieving pain associated with oral surgery. Am J Ther 2002;9(2):89-97.
3. Dionne RA, Berthold CW. Therapeutic uses of non-steroidal anti-inflammatory drugs in dentistry. Crit Rev Oral Biol Med 2001;12:315-30.
4. Chen LC, Elliott RA, Ashcroft DM. Systematic review of the analgesic efficacy and tolerability of COX-2 inhibitors in post-operative pain control. J Clin Pharm Ther 2004;29:215-29.
5. Christensen KS, Cawkwell GD. Valdecoxib versus rofecoxib in acute postsurgical pain: results of a randomized controlled trial. J Pain Symptom Manage 2004;27:460-70.
6. Cicconetti A, Bartoli A, Ripari F, Ripari A. COX-2 selective inhibitors: a literature review of analgesic efficacy and safety in oral-maxillofacial surgery. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2004;97(2):139-46.
7. Fine PG. The role of rofecoxib, a cyclooxygenase-2-specific inhibitor, for the treatment of non-cancer pain: a review. J Pain 2002;3:272-83.
8. May N, Epstein J, Osborne B. Selective COX-2 inhibitors: a review of their therapeutic potential and safety in dentistry. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2001;92:399-405.
9. Jeske AH. Selecting new drugs for pain control: evidence-based decision or clinical impressions? JADA 2002;133:1052-6.
10. Mukherjee D, Nissen SE, Topol EJ. Risk of cardiovascular events associated with selective COX-2 inhibitors. JAMA 2001;286:954-9.
11. Topol EJ. Arthritis medicines and cardiovascular events: 'house of coxibs.' JAMA 2005;293:366-8.
12. Bresalier RS, Sandler RS, Quan H, et al. Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial. N Engl J Med 2005;352:1092-102.
13. Graham DJ, Campen D, Hui R, et al. Risk of acute myocardial infarction and sudden cardiac death in patients treated with cyclooxygenase 2 selective and non-selective non-steroidal anti-inflammatory drugs: nested case-control study. Lancet 2005;365:475-81.
14. Nussmeier NA, Whelton AA, Brown MT, et al. Complications of the COX-2 inhibitors parecoxib and valdecoxib after cardiac surgery. N Engl J Med 2005;352:1081-91.
15. Solomon SD, McMurray JJ, Pfeffer MA, et al. Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention. N Engl J Med 2005;352:1071-80.
16. Chandrasekharan NV, Simmons DL. The cyclooxygenases. Genome Biol 2004;5:241.
17. FitzGerald GA, Patrono C. The coxibs, selective inhibitors of cyclooxygenase-2. N Engl J Med 2001;345:433-42.
18. Linton MF, Fazio S. Cyclooxygenase-2 and inflammation in atherosclerosis. Curr Opin Pharmacol 2004;4(2):116-23.
19. Fu JY, Masferrer JL, Seibert K, Raz A, Needleman P. The induction and suppression of prostaglandin H2 synthase (cycloooxygenase) in human monocytes. J Biol Chem 1990;265:16737-40.
20. Simon LS. Role and regulation of cyclooxygenase-2 during inflammation. Am J Med 1999;106(5B):37S-42S.
21. Chandrasekharan NV, Dai H, Roos LT, et al. COX-3, a cyclooxygenase-1 variant inhibited by acetaminophen and other analgesic/antipyretic drugs: cloning, structure, and expression. Proc Natl Acad Sci U S A 2002;99:13926-31.
22. Davies NM, Good RL, Roupe KA, Yanez JA. Cyclooxygenase-3: axiom, dogma, anomaly, enigma or splice error?-not as easy as 1, 2, 3. J Pharm Pharm Sci 2004;7:217-26.
23. Dou W, Jiao Y, Goorha S, Raghow R, Ballou LR. Nociception and the differential expression of cyclooxygenase-1 (COX-1), the COX-1 variant retaining intron-1 (COX-1v), and COX-2 in mouse dorsal root ganglia (DRG). Prostaglandins Other Lipid Mediat 2004;74(1-4):29-43.
24. Lipsky PE. The clinical potential of cyclooxygenase-2-specific inhibitors. Am J Med 1999;106(5B):51S-7S.
25. Raskin JB. Gastrointestinal effects of nonsteroidal anti-inflammatory therapy. Am J Med 1999;106(5B):3S-12S.
26. Patrono C, Coller B, FitzGerald GA, Hirsh J, Roth G. Platelet-active drugs: the relationships among dose, effectiveness, and side effects: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 2004;126(3 supplement):234S-64S.
27. Psaty BM, Furberg CD. COX-2 inhibitors: lessons in drug safety. N Engl J Med 2005;352:1133-5.
28. Schafer AI. Effects of nonsteroidal anti-inflammatory therapy on platelets. Am J Med 1999;106(5B):25S-36S.
29. Ehrich EW, Dallob A, De Lepeleire I, et al. Characterization of rofecoxib as a cycloooxygenase-2 isoform inhibitor and demonstration of analgesia in the dental pain model. Clin Pharmacol Ther 1999;65:336-47.
30. Malmstrom K, Daniels S, Kotey P, Seidenberg BC, Desjardins PJ. Comparison of rofecoxib and celecoxib, two cyclooxygenase-2 inhibitors, in postoperative dental pain: a randomized, placebo- and active-comparator-controlled clinical trial. Clin Ther 1999;21:1653-63.
31. Morrison BW, Christensen S, Yuan W, Brown J, Amlani S, Seidenberg B. Analgesic efficacy of the cyclooxygenase-2-specific inhibitor rofecoxib in post-dental surgery pain: a randomized, controlled trial. Clin Ther 1999;21:943-53.
32. Chang DJ, Fricke JR, Bird SR, Bohidar NR, Dobbins TW, Geba GP. Rofecoxib versus codeine/acetaminophen in postoperative dental pain: a double-blind, randomized, placebo- and active comparator-controlled clinical trial. Clin Ther 2001;23:1446-55.
33. Doyle G, Jayawardena S, Ashraf E, Cooper SA. Efficacy and tolerability of nonprescription ibuprofen versus celcoxib for dental pain. J Clin Pharmacol 2002;42:912-9.
34. Khan AA, Brahim JS, Rowan JS, Dionne RA. In vivo selectivity of a selective cyclooxygenase 2 inhibitor in the oral surgery model. Clin Pharmacol Ther 2002;72(1):44-9.
35. Chang DJ, Desjardins PJ, Chen E, et al. Comparison of the analgesic efficacy of rofecoxib and enteric-coated diclofenac sodium in the treatment of postoperative dental pain: a randomized, placebo-controlled clinical trial. Clin Ther 2002;24:490-503.
36. Malmstrom K, Fricke JR, Kotey P, Kress B, Morrison B. A comparison of rofecoxib versus celecoxib in treating pain after dental surgery: a single-center, randomized, double-blind, placebo- and active-comparator- controlled, parallel-group, single-dose study using the dental impaction model. Clin Ther 2002;24:1549-60.
37. Jackson ID, Heidemann BH, Wilson J, Power I, Brown RD. Double-blind, randomized, placebo-controlled trial comparing rofecoxib with dexketoprofen trometamol in surgical dentistry. Br J Anaesth 2004;92:675-80.
38. Zelenakas K, Fricke JR Jr, Jaywardene S, Kellstein D. Analgesic effect of single oral doses of lumiracoxib and ibuprofen in patients with postoperative dental pain. Int J Clin Pract 2004;58:251-6.
39. Kellstein D, Ott D, Jayawardene S, Fricke J. Analgesic efficacy of a single dose of lumiracoxib compared to rofecoxib, celecoxib and placebo in the treatment of post-operative dental pain. Int J Clin Pract 2004;58:244-50.
40. Chang DJ, Desjardin PJ, King TR, Erb T, Geba GP. The analgesic efficacy of etoricoxib compared with oxycodone/acetaminophen in an acute postoperative pain model: a randomized, double-blind clinical trial (published correction appears in Anesth Analg 2005;101:644. Anesth Analg 2004;99:807-15.
41. Korn S, Vassil TC, Kotey P-A, Fricke JR Jr. Comparison of rofecoxib and oxycodone plus acetaminophen in the treatment of acute pain: a randomized, double-blind, placebo-controlled study in patients with moderate to severe postoperative pain in the third molar extraction model. Clin Ther 2004;26:769-78.
42. Chang DJ, Desjardins PJ, Bird SR, et al. Comparison of rofecoxib and a multidose oxycodone/acetaminophen regimen for the treatment of acute pain following oral surgery: a randomized controlled trial. Curr Med Res Opin 2004;20:934-49.
43. Norholt SE. Treatment of acute pain following removal of mandibular third molars: use of the dental pain model in pharmacological research and development of a comparable animal model. Int J Oral Maxillofac Surg 1998;27(supplement 1):1-41.
44. Moore PA, Hersh EV. Celecoxib and rofecoxib: the role of COX-2 inhibitors in dental practice. JADA 2001;132:451-6.
45. Savage MG, Henry MA. Preoperative nonsterodial anti-inflammatory agents: review of the literature. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2004;98(2):146-52.
46. Lacy CF, Armstrong LL, Goldman MP, Lance LL. Drug information handbook. 12th ed. Hudson, Ohio: Lexi-Comp; 2004:1290.
47. Laine L, Maller ES, Yu C, Quan H, Simon T. Ulcer formation with low-dose enteric-coated aspirin and the effect of COX-2 selective inhibition: a double-blind trial. Gastroenterology 2004;127:395-402.
48. Schnitzer TJ, Burmester GR, Mysler E, et al. Comparison of lumiracoxib with naproxen and ibuprofen in the Therapeutic Arthritis Research and Gastrointestinal Event Trial (TARGET), reduction in ulcer complications: randomised controlled trial. Lancet 2004;364:665-74.
49. Silverstein FE, Faich G, Goldstein JL, et al. Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study-a randomized controlled trial. Celecoxib Long-term Arthritis Safety Study. JAMA 2000;284:1247-55.